Skip to main content

Clinical Neuroimmunology

The group of Clinical Neuroimmunology - Centre d'Esclerosi Múltiple de Catalunya (Cemcat) at the Vall d'Hebron Institut de Recerca (VHIR) is a multidisciplinary group dedicated to clinical assistance, physical and cognitive rehabilitation, and clinical and basic research on multiple sclerosis (MS). Cemcat is a national but also an international reference center in the clinical assistance of MS patients. The research performed in the group is divided and further combined in clinical and basic research. In addition, basic research has a marked translational character since the ultimate goal of the group is to improve the quality of life of patients suffering from MS, through in-depth knowledge of the pathogenic mechanisms of the disease and the development of new and more effective therapeutic approaches. 

Team

Carmen Espejo Ruiz

Carmen Espejo Ruiz

Senior researcher
Clinical Neuroimmunology
Read more
Manuel Comabella Lopez

Manuel Comabella Lopez

Predoctoral researcher
Clinical Neuroimmunology
Read more
Mar Tintore Subirana

Mar Tintore Subirana

Predoctoral researcher
Clinical Neuroimmunology
Read more
Xavier Montalban Gairín

Xavier Montalban Gairín

Head of group
Clinical Neuroimmunology
Read more
Jordi Rio Izquierdo

Jordi Rio Izquierdo

Clinical Neuroimmunology
Read more
Nicolás Miguel Fissolo

Nicolás Miguel Fissolo

Postdoctoral researcher
Clinical Neuroimmunology
Read more
Carmen Espejo Ruiz

Carmen Espejo Ruiz

Senior researcher
Clinical Neuroimmunology
Read more
Manuel Comabella Lopez

Manuel Comabella Lopez

Predoctoral researcher
Clinical Neuroimmunology
Read more
Mar Tintore Subirana

Mar Tintore Subirana

Predoctoral researcher
Clinical Neuroimmunology
Read more
Xavier Montalban Gairín

Xavier Montalban Gairín

Head of group
Clinical Neuroimmunology
Read more
Jordi Rio Izquierdo

Jordi Rio Izquierdo

Clinical Neuroimmunology
Read more
Nicolás Miguel Fissolo

Nicolás Miguel Fissolo

Postdoctoral researcher
Clinical Neuroimmunology
Read more

Research lines

MRI measures of neurodegeneration in Multiple Sclerosis - Clinical implications

Lead scientist: Jaume Sastre-Garriga / Deborah Pareto Brain volumetry is about to take a central role in the management of patients with MS. Recent evidence suggests that the neurodegenerative process can be reliably estimated in vivo with the help of MRI and appropriate software tools, and that such measurements are clinically relevant both for prognosis as well as in monitoring of treatment response. In the Clinical Neuroimmunology Group, brain volumetry estimates have been already obtained using well-tested methodologies in selected cohorts and its clinical relevance has been confirmed. New, more sophisticated software tools to obtain in-depth measuring of brain and spinal cord areas are now being tested for clinical relevance. This has been achieved through collaboration with the MRI Unit at the Institut de Diagnòstic per la Imatge.

IP: Manuel Comabella Lopez, Carmen Espejo Ruiz, Jordi Barquinero Mañez, Nicolás Miguel Fissolo

Research for therapeutic targets and/or therapeutic approaches

5.1 Bone morphogenetic proteins (BMP) antagonism as a target to enhance neuroregeneration in multiple sclerosis Lead scientist: Carmen Espejo Because MS therapies are mainly conducted to modulate the immune response, in the last years new research lines have been established in order to better understand the mechanisms that regulate and/or mediate the neurodegenerative and neuroregenerative processes. Although neuroregeneration occurs in the adult central nervous system (CNS), several negative signals impede the restore of the damaged CNS. Some of these signals could be mediated by BMPs, since these proteins have a key role in the developing CNS and in the adult CNS neurogenesis. BMPs also have a prominent role in the development of the thymus as well as in the differentiation of T-cells. We aim to characterize the expression of BMPs, receptors and antagonists in MS lesions, quantify them in the CSF of MS patients and evaluate its prognostic value. We also aim to test the therapeutic potential of the administration of BMP4 and an antagonist of BMPs, noggin, in experimental autoimmune encephalomyelitis (EAE), an experimental model of MS. 5.2. Role of semaphorins 3A and 7A in neuroregeneration and immune regulation in EAE model Lead scientist: Carmen Espejo As BMPs, Semaphorins could also be involved in neurodegeneration in MS, as negative signals impeding the restoration of the damaged CNS. This project aims to study the role of semaphorin 3A (sema3A) and sema7A, two axonal guidance molecules also involved in the regulation of immune responses, in EAE pathogenesis as well as their therapeutic implications. 5.3 Microbiota as a therapeutic target in multiple sclerosis: preclinical trial of two probiotics and butyrate in two experimental models of multiple sclerosis Lead scientist: Carmen Espejo A series of recent studies reveal that gut microbiome can influence immune responses distant from mucosal surfaces. Immunological dysregulation is the cause of numerous human disorders such as autoimmune diseases. Aberrant central nervous system (CNS) autoimmunity arises as a consequence of the lost of the normal immune tolerance to CNS self-antigens. Commensal microbiota affects the autoreactivity of peripheral immune cells to the CNS. The main objective of this project is to test whether the administration of two probiotics and butyrate has a beneficial effect in MS experimental model. 5.4. Tolerance induction in experimental autoimmune encephalomyelitis using gene therapy Lead scientists: Jordi Barquinero / Carmen Espejo Previous collaboration works with the group of Gene and Cell Therapy of our institution resulted in the development of a therapeutic strategy in which bone marrow cells were genetically modified to express a self-antigen with the aim to induce antigen-specific tolerance. We could see a therapeutic effect even in the absence of myeloablation, thus suggesting that a concrete population of cells generated in the cell culture, but not cells with a repopulating capacity, were responsible for the therapeutic effect seen in these mice. We have identified a candidate population, called myeloid derived suppressor cells that might be mediating the antigen-specific effect. 5.5. Genomic signature-based small molecule screening of neural stem cells to identify novel compounds to enhance oligodendrogenesis Lead scientist: Carme Costa Genomic signatures will be defined in the different stages of differentiation from neural stem cells to mature oligodendrocyte. The signatures will be used to identify new drugs that could induce oligodendrogenesis. In vitro validation will be performed to confirm that the addition of these compounds to cells under different stages of lineage commitment produces the desired gene expression signature. The selected compounds will be finally tested in vivo, in an experimental autoimmune encephalomyelitis mouse model. 5.6. Neurodegeneration and neuroregeneration in multiple sclerosis: search of biomarkers and potential new therapies Lead scientist: Nicolás Fissolo MS is a disease with two components: an inflammatory component that prevails in the initial stages (relapsing-remitting), and a neurodegenerative component that is more prominent in the advanced stages of the disease (progressive). Currently, therapeutic strategies in MS are highly effective to reduce or even suppress the inflammatory component of the disease; however, current treatments have proven to be totally ineffective in those patients in whom the neurodegenerative component predominates. Despite numerous studies in this field, the mechanisms of neurodegeneration that take place during the course of the disease are not well understood. We aim to identify biomarkers and potential therapeutic targets in the neurodegeneracion and neuroregeneration events taking place during the course of the EAE, the animal model of MS. 5.7 Targeting astrocytes to prevent neurodegeneration in patients with multiple sclerosis Lead scientist: Manuel Comabella The main objective of this proposal is a pharmacological modulation of astrocyte function in order to influence and modify neurodegeneration in MS patients.

IP: Nicolás Miguel Fissolo , Carmen Espejo Ruiz, Herena Eixarch Ahufinger

Study of the response to interferon-beta treatment in multiple sclerosis patients

3.1. Clinical, radiological and biological prognostic factors of response to treatment with interferon-beta Lead scientist: Jordi Río / Manuel Comabella Cohort study to establish outcome measures for clinical trials with clinical validity and clinical and radiological indicators associated with poor response to interferon-beta treatment. Study to identify gene signatures that may predict the good or bad response to interferon-beta in patients with MS before initiating treatment or in the first months of treatment and to identify gene expression signatures that may help to predict patients who will develop neutralizing antibodies against interferon-beta. 3.2. Clinical practice guideline on MS Lead scientist: Susana Otero A collaborative project to develop a clinical practice guideline on Multiple Sclerosis undertaken by Catalan Agency for Health Information, Assessment and Quality (AIAQS) and the Multiple Sclerosis Centre of Catalonia (Cemcat) was launched in 2010, with the participation of all opinion leading healthcare professionals involved in the management of MS. The guideline is based on the methodology set by the National Guidelines Program of the Spanish National Health Service using the recently established GRADE system of rating quality of evidence and grading strength of recommendations. The guideline is now finalized and available in its complete version and in a quick guide for easy access to the recommendations and algorithms. A Catalan and English version will also be available in the near future.

IP: Manuel Comabella Lopez, Jordi Rio Izquierdo

Susceptibility, diagnostic and prognostic markers in multiple sclerosis

2.1. Search for casual variants of genes associated with MS Lead scientist: Manuel Comabella This line of research seeks to identify causal variants responsible for the MS risk of genes found to be associated with the disease in GWAS by means if deep sequencing. 2.2. To develop dynamic risk scores according to dynamic prognostic models for MS based on clinical, biological and radiological variables Lead scientist: Mar Tintoré In particular: 1. Develop a dynamic risk score based on the evaluation of demographical, clinical, radiological, and biological factors that entail a higher risk of developing a second relapse after a clinically isolated syndrome (CIS), i.e. risk of CDMS, through building models of a dynamic nature. 2. Develop a dynamic risk score based on the evaluation of demographical, clinical, radiological, and biological factors entail a higher risk of progression of disability, as measured by the Expanded Disability Status Scale (EDSS) (Kurtzke Neurology 1983), in people who have suffered a CIS, also through building models of a dynamic nature. Since 1995, patients presenting with a CIS or first attack suggestive of MS are included in a prospective cohort study. One thousand and one hundred CIS patients with a median follow-up of almost 10 years, have been included up to now. Clinical variables (age, gender, topography of the syndrome), radiological variables (number of lesions, number of Barkhof criteria, topography of the lesions, atrophy measures), as well as biological markers (IgG and IgM oligoclonal bands). In a subgroup of patients additional biomarkers (neurofilaments light and heavy chains, fetuin A, GFAP, anti-neurofascin antibodies, anti-glycan panel, chitinase, S1P, etc.) are studied as predictors of conversion to MS and as predictors of disability progression. Mathematical and marginal structural models with different combinations of the variables listed above are investigated. 2.3. Neuropsychological assessment of neurocognitive deficits in patients with multiple sclerosis Lead scientist: Mª Jesús Arévalo Unified neuropsychological assessment is considered necessary to make comparisons between different groups of patients and to draw general conclusions as well as to evolve in the knowledge of cognitive impairment of patients. There is no consensus on protocols for neuropsychological assessment of people with MS in Catalonia and patient evaluations are performed disparately among different hospitals. Neurologists and neuropsychologists from 13 hospitals and patient foundations from Catalonia have held work meetings every two months since July 2012 to seek common work ground. Consensus has been reached as to a common neuropsychological protocol for the assessment of cognitive impairment in MS. We have set up a common database including clinical and neuropsychological variables recorded from interviews with patients introduced into one application. Our work group has been incorporated into the Neuropsychology Section of the Official College of Psychology of Catalonia. 2.4. Upper limbs function and psychometric properties of outcome measures Lead scientist: Núria Filló / Ingrid Galán Upper limbs impairment impacts on daily activities and social participation of persons with MS. Under-recognition of upper limb dysfunction may result in part from limited availability of performance-based and patient self-report measures that are validated for use in MS and that can be readily incorporated into clinical practice for screening and regularly scheduled assessments This line of research seeks to study the psychometric properties of outcome measures for upper limb function in MS. 2.5 EpidEMcat Lead scientist: Susana Otero The Multiple Sclerosis Centre of Catalonia (Cemcat) coordinates a project that aims to characterize the epidemiology of MS in Catalonia. For this purpose, a prospective registry of new cases of MS in Catalonia was set up in 2009 with the participation of 21 hospitals throughout Catalonia. Prevalence and incidence studies based on this population-based registry are being performed. A new research line on co-morbidity and healthcare resource utilization in MS patients is now starting. 2.6 Search of genetic modifiers associated with aggressive and benign disease courses Lead scientist: Manuel Comabella We aim to identify genetic variants that influence the course of the disease by means of exome sequencing of MS patients with divergent clinical courses, i.e. aggressive and benign disease courses. 2.7 Search of biomarkers for multiple sclerosis by RNA, microRNA and exome sequencing approaches Lead scientist: Manuel Comabella Biomarkers are needed in MS to understand the complex and multifactorial heterogeneity of the disease, particularly disease activity biomarkers that may help to distinguish between different MS clinical courses or activity phases of the disease. Here, we aimed to identify disease activity biomarkers in MS by applying RNA, microRNA, and DNA sequencing approaches.

IP: Manuel Comabella Lopez, Mar Tintore Subirana, Jaume Sastre Garriga, M Jesus Arevalo Navines, Susana Otero Romero

Projects

Complicacions neurològiques associades a cèl·lules CAR-T (CAR-T: Chimeric Antigen Receptor T-cell)

IP: Manuel Comabella Lopez
Collaborators: Andreu Vilaseca Jolonch, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 35000
Reference: HUVH/BPFSE_CM/2022/VILASECA
Duration: 01/06/2022 - 31/05/2023

Los astrocitos como diana en la prevención de la neurodegeneración en pacientes con esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Rucsanda Pinteac , Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 47268
Reference: 2018/VHIR/PINTEAC
Duration: 15/03/2019 - 14/03/2023

Utilidad de biomarcadores de suero y líquido cefalorraquídeo en la evaluación del pronóstico y respuesta a tratamiento en pacientes con fases iniciales de Esclerosis Multiple

IP: Manuel Comabella Lopez
Collaborators: Alvaro Cobo Calvo, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 180000
Reference: JR19/00007
Duration: 01/01/2020 - 31/12/2023

Junior Leader Incoming Postdoctoral Fellowships

IP: Xavier Montalban Gairín
Collaborators: Carmen Tur Gomez, Miriam Izquierdo Sans
Funding agency: Fundació "La Caixa"
Funding: 292500
Reference: CAIXA/INCOMING/2019/TUR
Duration: 28/09/2020 - 29/09/2023

Los astrocitos como diana en la prevención de la neurodegeneración en pacientes con esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Rucsanda Pinteac , Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 47268
Reference: 2018/VHIR/PINTEAC
Duration: 15/03/2019 - 14/03/2023

Utilidad de biomarcadores de suero y líquido cefalorraquídeo en la evaluación del pronóstico y respuesta a tratamiento en pacientes con fases iniciales de Esclerosis Multiple

IP: Manuel Comabella Lopez
Collaborators: Alvaro Cobo Calvo, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 180000
Reference: JR19/00007
Duration: 01/01/2020 - 31/12/2023

Estudio de la chitinase 3-like 1 como biomarcador pronóstico de neurodegeneración y potencial diana terapéutica en esclerosis múltiple para frenar la progresión de la enfermedad

IP: Manuel Comabella Lopez
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 60000
Reference: INT19/00070
Duration: 01/01/2020 - 31/12/2021

Junior Leader Incoming Postdoctoral Fellowships

IP: Xavier Montalban Gairín
Collaborators: Carmen Tur Gomez, Miriam Izquierdo Sans
Funding agency: Fundació "La Caixa"
Funding: 292500
Reference: CAIXA/INCOMING/2019/TUR
Duration: 28/09/2020 - 29/09/2023

NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients

IP: Sunny Malhotra Sareen
Collaborators: -
Funding agency: Fundación Merck Salud
Funding: 0.01
Reference: MERCK/PREM.SOLIDARIS/2020/MALHOTRA
Duration: 18/12/2020 - 18/12/2020

Sol·licitud Juan Rodés

IP: Xavier Montalban Gairín
Collaborators: Angela Vidal Jordana, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 135000
Reference: JR16/00024
Duration: 01/01/2017 - 21/04/2020

Los astrocitos como diana en la prevención de la neurodegeneración en pacientes con esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Rucsanda Pinteac , Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 47268
Reference: 2018/VHIR/PINTEAC
Duration: 15/03/2019 - 14/03/2023

Utilidad de biomarcadores de suero y líquido cefalorraquídeo en la evaluación del pronóstico y respuesta a tratamiento en pacientes con fases iniciales de Esclerosis Multiple

IP: Manuel Comabella Lopez
Collaborators: Alvaro Cobo Calvo, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 180000
Reference: JR19/00007
Duration: 01/01/2020 - 31/12/2023

Sol·licitud Juan Rodés

IP: Xavier Montalban Gairín
Collaborators: Angela Vidal Jordana, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 135000
Reference: JR16/00024
Duration: 01/01/2017 - 21/04/2020

Estudio del papel del inflamasoma en pacientes con esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Sunny Malhotra Sareen, Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 103807.4
Reference: SLT002/16/00357
Duration: 04/04/2017 - 31/12/2019

Sol·licitud Río Hortega

IP: Xavier Montalban Gairín
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 53732
Reference: CM17/00272
Duration: 01/01/2018 - 31/12/2019

Los astrocitos como diana en la prevención de la neurodegeneración en pacientes con esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Rucsanda Pinteac , Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 47268
Reference: 2018/VHIR/PINTEAC
Duration: 15/03/2019 - 14/03/2023

Búsqueda de variantes genéticas causales y estudio de sus implicaciones funcionales en pacientes con esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 46800
Reference: PRED-VHIR-2014-22
Duration: 05/02/2015 - 04/02/2018

Sol·licitud Juan Rodés

IP: Xavier Montalban Gairín
Collaborators: Angela Vidal Jordana, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 135000
Reference: JR16/00024
Duration: 01/01/2017 - 21/04/2020

Estudio del papel del inflamasoma en pacientes con esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Sunny Malhotra Sareen, Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 103807.4
Reference: SLT002/16/00357
Duration: 04/04/2017 - 31/12/2019

Sol·licitud d'intensificació

IP: Manuel Comabella Lopez
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 30000
Reference: INT17/00136
Duration: 01/01/2018 - 31/12/2018

Estabilització - Neuroimmunologia clínica

IP: Carmen Espejo Ruiz
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 121500
Reference: CPII13/00028
Duration: 01/04/2014 - 31/03/2017

Búsqueda de variantes genéticas causales y estudio de sus implicaciones funcionales en pacientes con esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 46800
Reference: PRED-VHIR-2014-22
Duration: 05/02/2015 - 04/02/2018

Sol·licitud Juan Rodés

IP: Xavier Montalban Gairín
Collaborators: Angela Vidal Jordana, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 135000
Reference: JR16/00024
Duration: 01/01/2017 - 21/04/2020

Trasllat de l'expedient de concessió del Pohl Hartmut, concedit principalment amb l'IDIBELL.

IP: Manuel Comabella Lopez
Collaborators: Miriam Izquierdo Sans
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 50000
Reference: FPDI-2013-17465
Duration: 10/10/2016 - 30/04/2017

Estabilització - Neuroimmunologia clínica

IP: Carmen Espejo Ruiz
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 121500
Reference: CPII13/00028
Duration: 01/04/2014 - 31/03/2017

Búsqueda de variantes genéticas causales y estudio de sus implicaciones funcionales en pacientes con esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 46800
Reference: PRED-VHIR-2014-22
Duration: 05/02/2015 - 04/02/2018

Investigation of the role of female hormonal factors in risk and prognosis of multiple sclerosis

IP: Xavier Montalban Gairín
Collaborators: Miriam Izquierdo Sans
Funding agency: ECTRIMS
Funding: 25000
Reference: ECTRIMS_CTFP2014
Duration: 02/11/2015 - 02/05/2016

Trasllat de l'expedient de concessió del Pohl Hartmut, concedit principalment amb l'IDIBELL.

IP: Manuel Comabella Lopez
Collaborators: Miriam Izquierdo Sans
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 50000
Reference: FPDI-2013-17465
Duration: 10/10/2016 - 30/04/2017

Search for new treatments for multiple sclerosis by means of massive screening of chemical compounds based on gene expressión through the use of connectivity maps

IP: Xavier Montalban Gairín
Collaborators: Miriam Izquierdo Sans
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 96000
Reference: JCI-2011-11491
Duration: 08/06/2012 - 07/06/2015

Ministerio de Ciencia

Estabilització - Neuroimmunologia clínica

IP: Carmen Espejo Ruiz
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 121500
Reference: CPII13/00028
Duration: 01/04/2014 - 31/03/2017

No disponible

IP: Xavier Montalban Gairín
Collaborators: Miriam Izquierdo Sans
Funding agency: Multiple Sclerosis International Federation (MSIF)
Funding: 4737.51
Reference: MS_MSIF-MCDO2012
Duration: 07/01/2013 - 31/12/2015

Búsqueda de variantes genéticas causales y estudio de sus implicaciones funcionales en pacientes con esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 46800
Reference: PRED-VHIR-2014-22
Duration: 05/02/2015 - 04/02/2018

Unitat de Neuroimmunologia Clínica (UNiC) - Centre d'Esclerosi Múltiple de Catalunya (CEM-Cat)

IP: Xavier Montalban Gairín
Collaborators: Herena Eixarch Ahufinger, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 144000
Reference: CD09/00363
Duration: 08/01/2010 - 19/08/2014

Research on molecular mechanisms of apoptosis in lymphocytes from patients with multiple sclerosis

IP: Xavier Montalban Gairín
Collaborators: Montserrat Moreno Sánchez, Miriam Izquierdo Sans
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 100980
Reference: JCI-2010-07580
Duration: 30/05/2011 - 29/05/2014

Ministerio de Ciencia

Función de las semaforinas 3A y 7A, moléculas de guía axonal, en la neurodegeneración y la regulación de la respuesta inmunitaria en la encefalomielitis autoinmune experimental

IP: Xavier Montalban Gairín
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 54000
Reference: FI10/00456
Duration: 15/09/2010 - 14/09/2014

Neuroimmunologia clínica

IP: Xavier Montalban Gairín
Collaborators: Angela Vidal Jordana, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 108000
Reference: CM10/00032
Duration: 03/01/2011 - 02/01/2014

Función de las proteínas de choque técnico (HSP, heat shock protein)-70 en la patogenia de la esclerosis múltiple

IP: Xavier Montalban Gairín
Collaborators: Carmen Espejo Ruiz, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 109804.5
Reference: MS07/00146
Duration: 01/01/2008 - 31/12/2013

Grup de Neuroimmunologia Clínica

IP: Xavier Montalban Gairín
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 109440
Reference: CD08/00187
Duration: 01/01/2009 - 22/04/2013

Unitat de Neuroimmunologia Clínica (UNiC) - Centre d'Esclerosi Múltiple de Catalunya (CEM-Cat)

IP: Xavier Montalban Gairín
Collaborators: Herena Eixarch Ahufinger, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 144000
Reference: CD09/00363
Duration: 08/01/2010 - 19/08/2014

Validación de marcadores biológicos asociados con la conversión a esclerosis múltiple en pacientes con sínddromes clínicos aislados

IP: Manuel Comabella Lopez
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 54000
Reference: FI09/00705
Duration: 07/09/2009 - 06/09/2013

Función de las proteínas de choque técnico (HSP, heat shock protein)-70 en la patogenia de la esclerosis múltiple

IP: Xavier Montalban Gairín
Collaborators: Carmen Espejo Ruiz, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 109804.5
Reference: MS07/00146
Duration: 01/01/2008 - 31/12/2013

Grup de Neuroimmunologia Clínica

IP: Xavier Montalban Gairín
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 109440
Reference: CD08/00187
Duration: 01/01/2009 - 22/04/2013

Unitat de Neuroimmunologia Clínica (UNiC) - Centre d'Esclerosi Múltiple de Catalunya (CEM-Cat)

IP: Xavier Montalban Gairín
Collaborators: Herena Eixarch Ahufinger, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 144000
Reference: CD09/00363
Duration: 08/01/2010 - 19/08/2014

Validación de marcadores biológicos asociados con la conversión a esclerosis múltiple en pacientes con sínddromes clínicos aislados

IP: Manuel Comabella Lopez
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 54000
Reference: FI09/00705
Duration: 07/09/2009 - 06/09/2013

Enfermedades neurológicas inmuno-mediadas

IP: Xavier Montalban Gairín
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 66104.64
Reference: CM07/00120
Duration: 15/01/2008 - 14/01/2011

Función de las proteínas de choque técnico (HSP, heat shock protein)-70 en la patogenia de la esclerosis múltiple

IP: Xavier Montalban Gairín
Collaborators: Carmen Espejo Ruiz, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 109804.5
Reference: MS07/00146
Duration: 01/01/2008 - 31/12/2013

Grup de Neuroimmunologia Clínica

IP: Xavier Montalban Gairín
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 109440
Reference: CD08/00187
Duration: 01/01/2009 - 22/04/2013

Vacunas de ADN en esclerosis múltiple.

IP: Xavier Montalban Gairín
Collaborators: Nicolás Miguel Fissolo
Funding agency: Fundació Institut de Recerca HUVH
Funding: 90000
Reference: POST/IR-HUVH/1/2008
Duration: 01/01/2009 - 31/12/2011

Enfermedades neurológicas inmuno-mediadas

IP: Xavier Montalban Gairín
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 66104.64
Reference: CM07/00120
Duration: 15/01/2008 - 14/01/2011

Función de las proteínas de choque técnico (HSP, heat shock protein)-70 en la patogenia de la esclerosis múltiple

IP: Xavier Montalban Gairín
Collaborators: Carmen Espejo Ruiz, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 109804.5
Reference: MS07/00146
Duration: 01/01/2008 - 31/12/2013

Grup de Neuroimmunologia Clínica

IP: Xavier Montalban Gairín
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 109440
Reference: CD08/00187
Duration: 01/01/2009 - 22/04/2013

Vacunas de ADN en esclerosis múltiple.

IP: Xavier Montalban Gairín
Collaborators: Nicolás Miguel Fissolo
Funding agency: Fundació Institut de Recerca HUVH
Funding: 90000
Reference: POST/IR-HUVH/1/2008
Duration: 01/01/2009 - 31/12/2011

Implementación de la metodología basada en los RNAi para la silenciación de genes con el propósito de estudiar la función de genes específicos tanto in vivo como in vitro. Estudio de la función de la heat shock protein (HSP)-70 en la patogenia de la esc

IP: -
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13622
Reference: PRED/IR-HUVH/05/2005
Duration: 01/01/2006 - 31/12/2009

Enfermedades neurológicas inmuno-mediadas

IP: Xavier Montalban Gairín
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 66104.64
Reference: CM07/00120
Duration: 15/01/2008 - 14/01/2011

Función de las proteínas de choque técnico (HSP, heat shock protein)-70 en la patogenia de la esclerosis múltiple

IP: Xavier Montalban Gairín
Collaborators: Carmen Espejo Ruiz, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 109804.5
Reference: MS07/00146
Duration: 01/01/2008 - 31/12/2013

Grup de Neuroimmunologia Clínica

IP: Xavier Montalban Gairín
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 109440
Reference: CD08/00187
Duration: 01/01/2009 - 22/04/2013

Implementación de la metodología basada en los RNAi para la silenciación de genes con el propósito de estudiar la función de genes específicos tanto in vivo como in vitro. Estudio de la función de la heat shock protein (HSP)-70 en la patogenia de la esc

IP: -
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13622
Reference: PRED/IR-HUVH/05/2005
Duration: 01/01/2006 - 31/12/2009

Enfermedades neurológicas inmuno-mediadas

IP: Xavier Montalban Gairín
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 66104.64
Reference: CM07/00120
Duration: 15/01/2008 - 14/01/2011

Función de las proteínas de choque técnico (HSP, heat shock protein)-70 en la patogenia de la esclerosis múltiple

IP: Xavier Montalban Gairín
Collaborators: Carmen Espejo Ruiz, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 109804.5
Reference: MS07/00146
Duration: 01/01/2008 - 31/12/2013

Caracterización de la respuesta de las células T CD4+ específicas de la mielina en las diferentes formas de esclerosis múltiple y preparación para un ensayo clínico Fase I/IIa para inducir tolerancia antígeno - específica en pacientes afectos de escleros

IP: -
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 144585
Reference: PI050806
Duration: 01/01/2006 - 31/12/2008

Implementación de la metodología basada en los RNAi para la silenciación de genes con el propósito de estudiar la función de genes específicos tanto in vivo como in vitro. Estudio de la función de la heat shock protein (HSP)-70 en la patogenia de la esc

IP: -
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13622
Reference: PRED/IR-HUVH/05/2005
Duration: 01/01/2006 - 31/12/2009

Caracterización de la respuesta de las células T CD4+ específicas de la mielina en las diferentes formas de esclerosis múltiple y preparación para un ensayo clínico Fase I/IIa para inducir tolerancia antígeno - específica en pacientes afectos de escleros

IP: -
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 144585
Reference: PI050806
Duration: 01/01/2006 - 31/12/2008

Análisis proteómico en líquido cefaloraquídeo y suero de pacientes con síndromes clínicos aislados sugestivos de esclerosis múltiple

IP: Mar Tintore Subirana
Collaborators: Manuel Comabella Lopez, Xavier Montalban Gairín
Funding agency: Instituto de Salud Carlos III
Funding: 141015
Reference: PI050588
Duration: 01/01/2006 - 31/01/2009

Neutralizing antibodies on Interferon beta in Multiple Sclerosis Contract No 018926

IP: Xavier Montalban Gairín
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 86400
Reference: FP6-NABINMS-18926
Duration: 01/01/2006 - 30/06/2009

Estudio prospectivo, mediante el uso de espectroscopia por resonancia magnética de pacientes con forma primaria progresiva inicial de esclerosis múltiple

IP: Jaume Sastre Garriga
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding:
Reference: BEFI 02/9115
Duration: 26/09/2002 - 25/09/2006

Implementación de la metodología basada en los RNAi para la silenciación de genes con el propósito de estudiar la función de genes específicos tanto in vivo como in vitro. Estudio de la función de la heat shock protein (HSP)-70 en la patogenia de la esc

IP: -
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13622
Reference: PRED/IR-HUVH/05/2005
Duration: 01/01/2006 - 31/12/2009

Immunomodulation in Multiple Sclerosis by Interferon ß. NIH grant application.

IP: Xavier Montalban Gairín
Collaborators: -
Funding agency: National Institutes of Health (NIH)
Funding: 1322196
Reference: 1 R01 NS42911
Duration: 01/01/2001 - 31/12/2006

Caracterización de la respuesta de las células T CD4+ específicas de la mielina en las diferentes formas de esclerosis múltiple y preparación para un ensayo clínico Fase I/IIa para inducir tolerancia antígeno - específica en pacientes afectos de escleros

IP: -
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 144585
Reference: PI050806
Duration: 01/01/2006 - 31/12/2008

Estudio prospectivo, mediante el uso de espectroscopia por resonancia magnética de pacientes con forma primaria progresiva inicial de esclerosis múltiple

IP: Jaume Sastre Garriga
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding:
Reference: BEFI 02/9115
Duration: 26/09/2002 - 25/09/2006

Immunomodulation in Multiple Sclerosis by Interferon ß. NIH grant application.

IP: Xavier Montalban Gairín
Collaborators: -
Funding agency: National Institutes of Health (NIH)
Funding: 1322196
Reference: 1 R01 NS42911
Duration: 01/01/2001 - 31/12/2006

Estudio de la subpoblación de linfocitos T CCR5+ en la etiopatogenia de la esclerosis múltiple (EM) y de la encefalomielitis autoinmune experimental (EAE).

IP: Xavier Montalban Gairín
Collaborators: Manuel Comabella Lopez, Carmen Espejo Ruiz
Funding agency: Instituto de Salud Carlos III
Funding: 47150
Reference: PI020160
Duration: 06/11/2002 - 06/11/2005

Estudio de la función de las células dentríticas (CD) en la esclerosis múltiple (EM). Diferencias entre las distintas formas clínicas de la enfermedad.

IP: Mar Tintore Subirana
Collaborators: Jordi Rio Izquierdo, Manuel Comabella Lopez
Funding agency: Instituto de Salud Carlos III
Funding: 31740
Reference: PI020158
Duration: 06/11/2002 - 06/11/2005

Estudio prospectivo, mediante el uso de espectroscopia por resonancia magnética de pacientes con forma primaria progresiva inicial de esclerosis múltiple

IP: Jaume Sastre Garriga
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding:
Reference: BEFI 02/9115
Duration: 26/09/2002 - 25/09/2006

Immunomodulation in Multiple Sclerosis by Interferon ß. NIH grant application.

IP: Xavier Montalban Gairín
Collaborators: -
Funding agency: National Institutes of Health (NIH)
Funding: 1322196
Reference: 1 R01 NS42911
Duration: 01/01/2001 - 31/12/2006

Estudio de la subpoblación de linfocitos T CCR5+ en la etiopatogenia de la esclerosis múltiple (EM) y de la encefalomielitis autoinmune experimental (EAE).

IP: Xavier Montalban Gairín
Collaborators: Manuel Comabella Lopez, Carmen Espejo Ruiz
Funding agency: Instituto de Salud Carlos III
Funding: 47150
Reference: PI020160
Duration: 06/11/2002 - 06/11/2005

Estudio de la función de las células dentríticas (CD) en la esclerosis múltiple (EM). Diferencias entre las distintas formas clínicas de la enfermedad.

IP: Mar Tintore Subirana
Collaborators: Jordi Rio Izquierdo, Manuel Comabella Lopez
Funding agency: Instituto de Salud Carlos III
Funding: 31740
Reference: PI020158
Duration: 06/11/2002 - 06/11/2005

Estudio prospectivo, mediante el uso de espectroscopia por resonancia magnética de pacientes con forma primaria progresiva inicial de esclerosis múltiple

IP: Jaume Sastre Garriga
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding:
Reference: BEFI 02/9115
Duration: 26/09/2002 - 25/09/2006

Immunomodulation in Multiple Sclerosis by Interferon ß. NIH grant application.

IP: Xavier Montalban Gairín
Collaborators: -
Funding agency: National Institutes of Health (NIH)
Funding: 1322196
Reference: 1 R01 NS42911
Duration: 01/01/2001 - 31/12/2006

Estudio de la subpoblación de linfocitos T CCR5+ en la etiopatogenia de la esclerosis múltiple (EM) y de la encefalomielitis autoinmune experimental (EAE).

IP: Xavier Montalban Gairín
Collaborators: Manuel Comabella Lopez, Carmen Espejo Ruiz
Funding agency: Instituto de Salud Carlos III
Funding: 47150
Reference: PI020160
Duration: 06/11/2002 - 06/11/2005

Estudio de la función de las células dentríticas (CD) en la esclerosis múltiple (EM). Diferencias entre las distintas formas clínicas de la enfermedad.

IP: Mar Tintore Subirana
Collaborators: Jordi Rio Izquierdo, Manuel Comabella Lopez
Funding agency: Instituto de Salud Carlos III
Funding: 31740
Reference: PI020158
Duration: 06/11/2002 - 06/11/2005

Estudio prospectivo, mediante el uso de espectroscopia por resonancia magnética de pacientes con forma primaria progresiva inicial de esclerosis múltiple

IP: Jaume Sastre Garriga
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding:
Reference: BEFI 02/9115
Duration: 26/09/2002 - 25/09/2006

Immunomodulation in Multiple Sclerosis by Interferon ß. NIH grant application.

IP: Xavier Montalban Gairín
Collaborators: -
Funding agency: National Institutes of Health (NIH)
Funding: 1322196
Reference: 1 R01 NS42911
Duration: 01/01/2001 - 31/12/2006

Estudio de la subpoblación de linfocitos T CCR5+ en la etiopatogenia de la esclerosis múltiple (EM) y de la encefalomielitis autoinmune experimental (EAE).

IP: Xavier Montalban Gairín
Collaborators: Manuel Comabella Lopez, Carmen Espejo Ruiz
Funding agency: Instituto de Salud Carlos III
Funding: 47150
Reference: PI020160
Duration: 06/11/2002 - 06/11/2005

Estudio de la función de las células dentríticas (CD) en la esclerosis múltiple (EM). Diferencias entre las distintas formas clínicas de la enfermedad.

IP: Mar Tintore Subirana
Collaborators: Jordi Rio Izquierdo, Manuel Comabella Lopez
Funding agency: Instituto de Salud Carlos III
Funding: 31740
Reference: PI020158
Duration: 06/11/2002 - 06/11/2005

Immunomodulation in Multiple Sclerosis by Interferon ß. NIH grant application.

IP: Xavier Montalban Gairín
Collaborators: -
Funding agency: National Institutes of Health (NIH)
Funding: 1322196
Reference: 1 R01 NS42911
Duration: 01/01/2001 - 31/12/2006

Estudio del papel de los factores neurotróficos en la esclerosis múltiple.

IP: Xavier Montalban Gairín
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 63466.88
Reference: 99/0961
Duration: 01/11/1999 - 01/11/2000

Estudio del papel de los factores neurotróficos en la esclerosis múltiple.

IP: Xavier Montalban Gairín
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 63466.88
Reference: 99/0961
Duration: 01/11/1999 - 01/11/2000

Publications

[Epidemiology of neuromyelitis optica spectrum. New and old challenges].

PMID: 34927702
Journal: REVISTA DE NEUROLOGIA
Year: 2022
Reference: Rev Neurol. 2022 Jan 1;74(1):22-34. doi: 10.33588/rn.7401.2021163.
Impact factor: 0.87
Publication type: Review in national publication
Authors: Sepulveda, M; Arrambide, G; Cobo-Calvo, A et al.
DOI: 10.33588/rn.7401.2021163

Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal.

PMID: 34850641
Journal: Multiple Sclerosis Journal
Year: 2022
Reference: Mult Scler. 2022 Jan;28(1):16-28. doi: 10.1177/13524585211059766. Epub 2021 Dec 1.
Impact factor: 6.312
Publication type: Paper in international publication
Authors: Coetzee, Timothy; Zaratin, Paola; Strum, Jon; Smith, Kathryn E; Thompson, Alan J; Carroll, William; Ciccarelli, Olga; Comi, Giancarlo; Cross, Anne; Donnelly, Alexis et al.
DOI: 10.1177/13524585211059766

Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.

PMID: 33764197
Journal: Multiple Sclerosis Journal
Year: 2022
Reference: Mult Scler. 2022 Jan;28(1):132-138. doi: 10.1177/13524585211005339. Epub 2021 Mar 25.
Impact factor: 6.312
Publication type: Paper in international publication
Authors: Portaccio, Emilio; Fonderico, Mattia; Hemmer, Bernhard; Derfuss, Tobias; Stankoff, Bruno; Selmaj, Krzysztof; Tintore, Mar; Amato, Maria Pia et al.
DOI: 10.1177/13524585211005339

CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event.

PMID: 33870790
Journal: Multiple Sclerosis Journal
Year: 2022
Reference: Mult Scler. 2022 Jan;28(1):71-81. doi: 10.1177/13524585211010082. Epub 2021 Apr 19.
Impact factor: 6.312
Publication type: Paper in international publication
Authors: Pinteac, Rucsanda; Granziera, Cristina; Sastre-Garriga, Jaume; Benkert, Pascal; Auger, Cristina; Kuhle, Jens; Montalban, Xavier; Rovira, Alex; Fissolo, Nicolas; Pareto, Deborah et al.
DOI: 10.1177/13524585211010082

Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references.

PMID: 33882422
Journal: NeuroImage-Clinical
Year: 2021
Reference: Neuroimage Clin. 2021;30:102659. doi: 10.1016/j.nicl.2021.102659. Epub 2021 Apr 6.
Impact factor: 4.881
Publication type: Paper in international publication
Authors: Simoes, Jorge, Ruggieri, Serena, Schregel, Katharina, Ropele, Stefan, Rocca, Maria A, Gasperini, Claudio, Gallo, Antonio, Schoonheim, Menno M, Amann, Michael, Yiannakas, Marios et al.
DOI: 10.1016/j.nicl.2021.102659

Systematic CT perfusion acquisition in acute stroke increases vascular occlusion detection and thrombectomy rates.

PMID: 34857668
Journal: Journal of NeuroInterventional Surgery
Year: 2021
Reference: J Neurointerv Surg. 2021 Dec 2. pii: neurintsurg-2021-018241. doi: 10.1136/neurintsurg-2021-018241.
Impact factor: 5.836
Publication type: Paper in international publication
Authors: Olive-Gadea, Marta, Requena, Manuel, Diaz, Facundo, Boned, Sandra, Garcia-Tornel, Alvaro, Muchada, Marian, Deck, Matias, Lozano, Prudencio, Rodriguez-Villatoro, Noelia, Juega, Jesus et al.
DOI: 10.1136/neurintsurg-2021-018241

Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients.

PMID: 34859704
Journal: Multiple Sclerosis Journal
Year: 2021
Reference: Mult Scler. 2021 Dec 3:13524585211061339. doi: 10.1177/13524585211061339.
Impact factor: 6.312
Publication type: Paper in international publication
Authors: Rovira, Alex, Corral, Juan Francisco, Auger, Cristina, Valverde, Sergi, Vidal-Jordana, Angela, Ng Wong, Yiken Karelys, Tintore, Mar, Pareto, Deborah, Aymerich, Francesc Xavier, Montalban, Xavier et al.
DOI: 10.1177/13524585211061339

Opportunities for Understanding MS Mechanisms and Progression With MRI Using Large-Scale Data Sharing and Artificial Intelligence.

PMID: 34607924
Journal: NEUROLOGY
Year: 2021
Reference: Neurology. 2021 Nov 23;97(21):989-999. doi: 10.1212/WNL.0000000000012884. Epub 2021 Oct 4.
Impact factor: 9.91
Publication type: Paper in international publication
Authors: Barkhof, Frederik, Vrenken, Hugo, Jenkinson, Mark, Pham, Dzung, Guttmann, Charles R G, Pareto, Deborah, Paardekooper, Michel, de Sitter, Alexandra, Rocca, Maria A, Wottschel, Viktor et al.
DOI: 10.1212/WNL.0000000000012884

Falls in People with Multiple Sclerosis: Risk Identification, Intervention, and Future Directions.

PMID: 33424479
Journal: International journal of MS care
Year: 2020
Reference: Int J MS Care. 2020 Nov-Dec;22(6):247-255. doi: 10.7224/1537-2073.2020-014. Epub 2020 Sep 14.
Impact factor: 0
Publication type: Paper in international publication
Authors: Coote, Susan, Santoyo-Medina, Carme, Kalron, Alon, Gunn, Hilary, Quinn, Gillian, Comber, Laura et al.
DOI: 10.7224/1537-2073.2020-014

Assessing life balance of European people with multiple sclerosis: A multicenter clinimetric study within the RIMS network.

PMID: 31915118
Journal: Multiple Sclerosis and Related Disorders
Year: 2020
Reference: Multiple Sclerosis and Related Disorders. 2020 Apr;39:101879.
Impact factor: 2.889
Publication type: Paper in international publication
Authors: Kos, Daphne, Ferdinand, Sofie, Duportail, Marijke, Eijssen, Isaline, Schouteden, Sofie, Kerkhofs, Lore, Jansa, Jelka, Fillo, Núria, Matuska, Kathleen, Beckerman, Heleen et al.
DOI: 10.1016/j.msard.2019.101879

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.

PMID: 33408681
Journal: Frontiers in Neurology
Year: 2020
Reference: Front Neurol. 2020 Dec 17;11:579438. doi: 10.3389/fneur.2020.579438. eCollection 2020.
Impact factor: 2.889
Publication type: Paper in international publication
Authors: Romero, Fernando, Laroni, Alicia, Uccelli, Antonio, Perez-Sempere, Angel, Saiz, Albert, Blanco, Yolanda, Galimberti, Daniela, Scarpini, Elio, Espejo, Carmen, Montalban, Xavier et al.
DOI: 10.3389/fneur.2020.579438

Palliative care in multiple sclerosis: European guideline.

PMID: 32513039
Journal: Multiple Sclerosis Journal
Year: 2020
Reference: Mult Scler. 2020 Aug;26(9):1009-1011. doi: 10.1177/1352458520926467. Epub 2020 Jun 9.
Impact factor: 5.412
Publication type: Paper in international publication
Authors: Solari, Alessandra, Oliver, David, Solari, Alessandra, Giordano, Andrea, Sastre-Garriga, Jaume, Kopke, Sascha, Rahn, Anne C, Kleiter, Ingo, Aleksovska, Katina, Battaglia, Mario A et al.
DOI: 10.1177/1352458520926467

Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG.

PMID: 31043474
Journal: NEUROLOGY
Year: 2019
Reference: Neurology. 2019 May 28;92(22):e2538-e2549. doi: 10.1212/WNL.0000000000007572. Epub 2019 May 1.
Impact factor: 8.689
Publication type: Paper in international publication
Authors: Waubant, Emmanuelle, Banwell, Brenda, Wassmer, Evangeline, Sormani, Maria-Pia, Amato, Maria-Pia, Hintzen, Rogier, Krupp, Lauren, Rostasy, Kevin, Tenembaum, Silvia, Chitnis, Tanuja et al.
DOI: 10.1212/WNL.0000000000007572

Multiple Sclerosis Lesion Synthesis in MRI Using an Encoder-Decoder U-NET

PMID: NOPMID0063
Journal: IEEE Access
Year: 2019
Reference: IEEE Access. 2019;7:25171-84. doi: 10.1109/ACCESS.2019.2900198
Impact factor: 4.098
Publication type: Paper in international publication
Authors: Salem, Mostafa, Valverde, Sergi, Cabezas, Mariano, Pareto Onghena, Deborah, Oliver, Arnau, Salvi, Joaquim, Rovira Cañellas, Alex, Llado, Xavier et al.
DOI: 10.1109/ACCESS.2019.2900198

Correction: Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study.

PMID: 31596725
Journal: JOURNAL OF MEDICAL INTERNET RESEARCH
Year: 2019
Reference: J Med Internet Res. 2019 Oct 8;21(10):e16287. doi: 10.2196/16287.
Impact factor: 4.945
Publication type: Letter or abstract
Authors: Midaglia, Luciana, Mulero, Patricia, Montalban, Xavier, Graves, Jennifer, Hauser, Stephen L, Julian, Laura, Baker, Michael, Schadrack, Jan, Gossens, Christian, Scotland, Alf et al.
DOI: 10.2196/16287

Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study.

PMID: 31471961
Journal: JOURNAL OF MEDICAL INTERNET RESEARCH
Year: 2019
Reference: J Med Internet Res. 2019 Aug 30;21(8):e14863. doi: 10.2196/14863.
Impact factor: 4.945
Publication type: Paper in international publication
Authors: Midaglia, Luciana, Mulero, Patricia, Montalban, Xavier, Graves, Jennifer, Hauser, Stephen L, Julian, Laura, Baker, Michael, Schadrack, Jan, Gossens, Christian, Scotland, Alf et al.
DOI: 10.2196/14863

Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.

PMID: 30367633
Journal: Journal of Neuroinflammation
Year: 2018
Reference: J Neuroinflammation. 2018 Oct 26;15(1):296. doi: 10.1186/s12974-018-1336-9.
Impact factor: 5.193
Publication type: Paper in international publication
Authors: Montalban, Xavier, Malhotra, Sunny, Villar, Luisa M, Costa, Carme, Midaglia, Luciana, Cubedo, Marta, Medina, Silvia, Fissolo, Nicolas, Rio, Jordi, Castillo, Joaquin et al.
DOI: 10.1186/s12974-018-1336-9

NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.

PMID: 29117789
Journal: Multiple Sclerosis Journal
Year: 2018
Reference: Mult Scler. 2018 Oct;24(11):1507-1510. doi: 10.1177/1352458517739137. Epub 2017 Nov 9.
Impact factor: 5.28
Publication type: Paper in international publication
Authors: Malhotra, Sunny, Sorosina, Melissa, Rio, Jordi, Peroni, Silvia, Midaglia, Luciana, Villar, Luisa M, Alvarez-Cermeno, Jose C, Schroeder, Ina, Esposito, Federica, Clarelli, Ferdinando et al.
DOI: 10.1177/1352458517739137

Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations.

PMID: 28445084
Journal: Multiple Sclerosis Journal
Year: 2018
Reference: Mult Scler. 2018 May;24(6):721-727. doi: 10.1177/1352458517707070. Epub 2017 Apr 26.
Impact factor: 5.28
Publication type: Paper in international publication
Authors: Huerga, Elena, Mitjana, Raquel, Auger, Cristina, Tintore, Mar, Rovira, Alex, Montalban, Xavier, Otero-Romero, Susana, Arrambide, Georgina, Pareto, Deborah, Vidal-Jordana, Angela et al.
DOI: 10.1177/1352458517707070

Ocrelizumab: a new milestone in multiple sclerosis therapy.

PMID: 29774057
Journal: Therapeutic Advances in Neurological Disorders
Year: 2018
Reference: Ther Adv Neurol Disord. 2018 May 10;11:1756286418773025. doi: 10.1177/1756286418773025. eCollection 2018.
Impact factor: 4.75
Publication type: Review in international publication
Authors: Mulero, Patricia, Midaglia, Luciana, Montalban, Xavier et al.
DOI: 10.1177/1756286418773025

Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI.

PMID: 27456965
Journal: EUROPEAN RADIOLOGY
Year: 2017
Reference: Eur Radiol. 2017 Apr;27(4):1361-1368. doi: 10.1007/s00330-016-4503-3. Epub 2016 Jul 25.
Impact factor: 3.967
Publication type: Paper in international publication
Authors: Aymerich, F X, Auger, C, Alcaide-Leon, P, Pareto, D, Corral, J F, Mitjana, R, Sastre-Garriga, J, Montalban, X, Rovira, A, Huerga, E et al.
DOI: 10.1007/s00330-016-4503-3

Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.

PMID: 28063616
Journal: JOURNAL OF NEUROIMMUNOLOGY
Year: 2017
Reference: J Neuroimmunol. 2017 Feb 15;303:62-65. doi: 10.1016/j.jneuroim.2016.12.006. Epub 2016 Dec 18.
Impact factor: 2.536
Publication type: Paper in international publication
Authors: Matute-Blanch, Clara, Rio, Jordi, Villar, Luisa M, Midaglia, Luciana, Malhotra, Sunny, Alvarez-Cermeno, Jose C, Vidal-Jordana, Angela, Montalban, Xavier, Comabella, Manuel et al.
DOI: 10.1016/j.jneuroim.2016.12.006

Automated tissue segmentation of MR brain images in the presence of white matter lesions.

PMID: 27598104
Journal: MEDICAL IMAGE ANALYSIS
Year: 2017
Reference: Med Image Anal. 2017 Jan;35:446-457. doi: 10.1016/j.media.2016.08.014. Epub 2016 Aug 30.
Impact factor: 4.565
Publication type: Paper in international publication
Authors: Valverde, Sergi, Oliver, Arnau, Roura, Eloy, Gonzalez-Villa, Sandra, Pareto, Deborah, Vilanova, Joan C, Ramio-Torrenta, Lluis, Rovira, Alex, Llado, Xavier et al.
DOI: 10.1016/j.media.2016.08.014

Grey matter atrophy is associated with disability increase in natalizumab-treated patients.

PMID: 27354019
Journal: Multiple Sclerosis Journal
Year: 2017
Reference: Mult Scler. 2017 Apr;23(4):556-566. doi: 10.1177/1352458516656808. Epub 2016 Jul 11.
Impact factor: 4.671
Publication type: Paper in international publication
Authors: Ciampi, Ethel, Pareto, Deborah, Sastre-Garriga, Jaume, Vidal-Jordana, Angela, Tur, Carmen, Rio, Jordi, Tintore, Mar, Auger, Cristina, Rovira, Alex, Montalban, Xavier et al.
DOI: 10.1177/1352458516656808

A 10-year follow-up of the European multicenter trial of interferon beta-1b in secondary-progressive multiple sclerosis.

PMID: 26362898
Journal: Multiple Sclerosis Journal
Year: 2016
Reference: Mult Scler. 2016 Apr;22(4):533-43. doi: 10.1177/1352458515594440. Epub 2015 Sep 11.
Impact factor: 4.822
Publication type: Paper in international publication
Authors: Gugleta, K, Ecsedi, M, Lienert, C, Amato, M P, Baum, K, Buttmann, M, Bayas, A, Brassat, D, Brochet, B, Confavreux, C et al.
DOI: 10.1177/1352458515594440

Structural MRI correlates of cognitive impairment in patients with multiple sclerosis: A Multicenter Study.

PMID: 26833969
Journal: HUMAN BRAIN MAPPING
Year: 2016
Reference: Hum Brain Mapp. 2016 Apr;37(4):1627-44. doi: 10.1002/hbm.23125. Epub 2016 Feb 2.
Impact factor: 4.962
Publication type: Paper in international publication
Authors: Preziosa, Paolo, Rocca, Maria A, Pagani, Elisabetta, Stromillo, Maria Laura, Enzinger, Christian, Gallo, Antonio, Hulst, Hanneke E, Atzori, Matteo, Pareto, Deborah, Riccitelli, Gianna C et al.
DOI: 10.1002/hbm.23125

MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes.

PMID: 26604134
Journal: HUMAN MOLECULAR GENETICS
Year: 2016
Reference: Hum Mol Genet. 2016 Jan 15;25(2):308-16. doi: 10.1093/hmg/ddv473. Epub 2015 Nov 24.
Impact factor: 5.985
Publication type: Paper in international publication
Authors: Comabella, Manuel, Canto, Ester, Nurtdinov, Ramil, Rio, Jordi, Villar, Luisa M, Picon, Carmen, Castillo, Joaquin, Fissolo, Nicolas, Aymerich, Xavier, Auger, Cristina et al.
DOI: 10.1093/hmg/ddv473

[Response to treatment with interferon beta in patients with multiple sclerosis. Validation of the Rio Score].

PMID: 27439483
Journal: REVISTA DE NEUROLOGIA
Year: 2016
Reference: Rev Neurol. 2016 Aug 16;63(4):145-50.
Impact factor: 0.684
Publication type: Paper in national publication
Authors: Montalban, X, Comabella, M, Rio, J, Rovira, A, Blanco, Y, Sainz, A, Perkal, H, Robles, R, Ramio-Torrenta, Ll, Diaz, R M et al.
DOI:

Significant clinical worsening after natalizumab withdrawal: Predictive factors.

PMID: 25392320
Journal: Multiple Sclerosis Journal
Year: 2015
Reference: Mult Scler. 2015 May;21(6):780-5. doi: 10.1177/1352458514549401. Epub 2014 Nov 12.
Impact factor: 4.863
Publication type: Paper in international publication
Authors: Tintore, M, Tur, C, Perez-Miralles, F, Auger, C, Rio, J, Nos, C, Arrambide, G, Comabella, M, Galan, I, Castillo, J et al.
DOI: 10.1177/1352458514549401

Brain atrophy in natalizumab-treated patients: A 3-year follow-up.

PMID: 25392330
Journal: Multiple Sclerosis Journal
Year: 2015
Reference: Mult Scler. 2015 May;21(6):749-56. doi: 10.1177/1352458514556300. Epub 2014 Nov 12.
Impact factor: 4.863
Publication type: Paper in international publication
Authors: Rovira, A, Sastre-Garriga, J, Tur, C, Pareto, D, Vidal-Jordana, A, Auger, C, Rio, J, Huerga, E, Tintore, M, Montalban, X et al.
DOI: 10.1177/1352458514556300

Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling.

PMID: 26740917
Journal: NeuroImage-Clinical
Year: 2015
Reference: Neuroimage Clin. 2015 Oct 28;9:640-7. doi: 10.1016/j.nicl.2015.10.012. eCollection 2015.
Impact factor: 2.526
Publication type: Paper in international publication
Authors: Valverde, Sergi, Oliver, Arnau, Roura, Eloy, Pareto, Deborah, Vilanova, Joan C, Ramio-Torrenta, Lluis, Sastre-Garriga, Jaume, Montalban, Xavier, Rovira, Alex, Llado, Xavier et al.
DOI: 10.1016/j.nicl.2015.10.012

Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta.

PMID: 26531701
Journal: JOURNAL OF NEUROIMMUNOLOGY
Year: 2015
Reference: J Neuroimmunol. 2015 Nov 15;288:98-101. doi: 10.1016/j.jneuroim.2015.09.007. Epub 2015 Sep 25.
Impact factor: 2.467
Publication type: Paper in international publication
Authors: Negrotto, Laura, Canto, Ester, Tintore, Mar, Montalban, Xavier, Comabella, Manuel, Rio, Jordi et al.
DOI: 10.1016/j.jneuroim.2015.09.007

[Current description of multiple sclerosis].

PMID: 25732942
Journal: MED CLIN-BARCELONA
Year: 2014
Reference: Med Clin (Barc). 2014 Dec;143 Suppl 3:3-6. doi: 10.1016/S0025-7753(15)30002-6.
Impact factor: 1.252
Publication type: Review in national publication
Authors: Rio, Jordi, Montalban, Xavier et al.
DOI: 10.1016/S0025-7753(15)30002-6

Kinetic analysis of [11C]vorozole binding in the human brain with positron emission tomography.

PMID: 24824855
Journal: MOL IMAGING
Year: 2014
Reference: Mol Imaging. 2014 May;13(3):1-12.
Impact factor: 2.191
Publication type: Paper in international publication
Authors: Logan, Jean, Kim, Sung Won, Pareto, Deborah, Telang, Frank, Wang, Gene-Jack, Fowler, Joanna S, Biegon, Anat et al.
DOI:

HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-beta therapy in multiple sclerosis.

PMID: 24748646
Journal: J MED GENET
Year: 2014
Reference: J Med Genet. 2014 Jun;51(6):395-400. doi: 10.1136/jmedgenet-2014-102348. Epub 2014 Apr 19.
Impact factor: 5.636
Publication type: Paper in international publication
Authors: Nunez, Concepcion, Rio, Jordi, Fernandez-Arquero, Miguel, Arroyo, Rafael, Montalban, Xavier, Fernandez, Oscar, Oliver-Martos, Begona, Leyva, Laura, Comabella, Manuel, Urcelay, Elena et al.
DOI: 10.1136/jmedgenet-2014-102348

Activation-induced cell death in T lymphocytes from multiple sclerosis patients.

PMID: 24793898
Journal: J NEUROIMMUNOL
Year: 2014
Reference: J Neuroimmunol. 2014 Jul 15;272(1-2):51-5. doi: 10.1016/j.jneuroim.2014.04.007. Epub 2014 Apr 16.
Impact factor: 2.786
Publication type: Paper in international publication
Authors: Moreno, Montserrat, Negrotto, Laura, Rio, Jordi, Moubarak, Rana, Martin, Isabel, Bustamante, Marta F, Comella, Joan X, Vidal-Jordana, Angela, Perez-Boza, Jennifer, Montalban, Xavier et al.
DOI: 10.1016/j.jneuroim.2014.04.007

In vivo imaging of brain aromatase in female baboons: [11C]vorozole kinetics and effect of the menstrual cycle.

PMID: 24447618
Journal: Molecular Imaging
Year: 2013
Reference: Mol Imaging. 2013 Nov-Dec;12(8). doi: 10.2310/7290.2013.00068.
Impact factor: 3.408
Publication type: Paper in international publication
Authors: Pareto, Deborah, Biegon, Anat, Alexoff, David, Carter, Pauline, Shea, Coreen, Muench, Lisa, Xu, Youwen, Fowler, Joanna S, Kim, Sunny W, Logan, Jean et al.
DOI: 10.2310/7290.2013.00068

Optimization of [(11)C]raclopride positron emission tomographic rat studies: comparison of methods for image quantification.

PMID: 23651503
Journal: Molecular Imaging
Year: 2013
Reference: Mol Imaging. 2013 Jun;12(4):257-62.
Impact factor: 3.408
Publication type: Paper in international publication
Authors: Pareto, Deborah, Ruiz, Alba, Gispert, Juan Domingo, Millan, Olga, Torrent, Elia, Farre, Magi, Abasolo, Ibane, Llop, Jordi et al.
DOI:

Clinical impact of early brain atrophy in clinically isolated syndromes.

PMID: 23652215
Journal: Multiple Sclerosis Journal
Year: 2013
Reference: Mult Scler. 2013 Dec;19(14):1878-86. doi: 10.1177/1352458513488231. Epub 2013 May 7.
Impact factor: 4.472
Publication type: Paper in international publication
Authors: Montalban, X, Rovira, A, Huerga, E, Auger, C, Perez-Miralles, F, Sastre-Garriga, J, Tintore, M, Arrambide, G, Nos, C, Perkal, H et al.
DOI: 10.1177/1352458513488231

Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-beta.

PMID: 23637780
Journal: PLoS One
Year: 2013
Reference: PLoS One. 2013 Apr 18;8(4):e60994. doi: 10.1371/journal.pone.0060994. Print 2013.
Impact factor: 3.73
Publication type: Paper in international publication
Authors: Montalban, Xavier, Bustamante, Marta F, Nurtdinov, Ramil N, Rio, Jordi, Comabella, Manuel et al.
DOI: 10.1371/journal.pone.0060994

In vivo molecular imaging of the GABA/benzodiazepine receptor complex in the aged rat brain.

PMID: 21272959
Journal: NEUROBIOLOGY OF AGING
Year: 2012
Reference: Neurobiol Aging. 2012 Jul;33(7):1457-65. doi: 10.1016/j.neurobiolaging.2010.12.006. Epub 2011 Jan 26.
Impact factor: 6.189
Publication type: Paper in international publication
Authors: Abad, Sergio, Jimenez, Xavier, Figueiras, Francisca P, Popota, Foteini, Ruiz, Alba, Flotats, Nuria, Fernandez, Francisco J, Rocha, Milagros, Rovira, Mariana, Victor, Victor M et al.
DOI: 10.1016/j.neurobiolaging.2010.12.006

Which walking capacity tests to use in multiple sclerosis? A multicentre study providing the basis for a core set.

PMID: 21952098
Journal: Multiple Sclerosis Journal
Year: 2012
Reference: Mult Scler. 2012 Mar;18(3):364-71. doi: 10.1177/1352458511420598. Epub 2011 Sep 27.
Impact factor: 4.255
Publication type: Clinical guide
Authors: Gijbels, Domien, Dalgas, Ulrik, Romberg, Anders, de Groot, Vincent, Bethoux, Francois, Vaney, Claude, Gebara, Benoit, Medina, Carme Santoyo, Maamagi, Heigo, Rasova, Kamila et al.
DOI: 10.1177/1352458511420598

Effect of time of day on walking capacity and self-reported fatigue in persons with multiple sclerosis: a multi-center trial.

PMID: 21969239
Journal: Multiple Sclerosis Journal
Year: 2012
Reference: Mult Scler. 2012 Mar;18(3):351-7. doi: 10.1177/1352458511419881. Epub 2011 Oct 3.
Impact factor: 4.255
Publication type: Paper in international publication
Authors: Gijbels, D, Romberg, A, Santoyo, C, Gebara, B, de Noordhout, B Maertens, Knuts, K, Bethoux, F, de Groot, V, Vaney, C, Dalgas, U et al.
DOI: 10.1177/1352458511419881

Whole-body vibration training for patients with neurodegenerative disease.

PMID: 22336858
Journal: Cochrane Database of Systematic Reviews
Year: 2012
Reference: Cochrane Database Syst Rev. 2012 Feb 15;(2):CD009097. doi: 10.1002/14651858.CD009097.pub2.
Impact factor: 5.912
Publication type: Review in national publication
Authors: Roque i Figuls, Marta, Romero-Rodriguez, Daniel, Bonfill Cosp, Xavier, Santoyo Medina, Carme, Fort Vanmeerhaeghe, Azahara, Rigau Comas, David, Sitja Rabert, Merce et al.
DOI: 10.1002/14651858.CD009097.pub2

Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis: Five-Year Clinical Trial Follow-up.

PMID: 22084124
Journal: ARCHIVES OF NEUROLOGY
Year: 2011
Reference: Arch Neurol. 2011 Nov;68(11):1421-7.
Impact factor: 7.108
Publication type: Paper in international publication
Authors: Tur, Carmen, Montalban, Xavier, Tintore, Mar, Nos, Carlos, Rio, Jordi, Aymerich, Francesc Xavier, Brieva, Luis, Tellez, Nieves, Perkal, Hector, Comabella, Manuel et al.
DOI: 10.1001/archneurol.2011.241

Implication of the toll-like receptor 4 pathway in the response to interferon-beta in multiple sclerosis.

PMID: 22028223
Journal: ANNALS OF NEUROLOGY
Year: 2011
Reference: Ann Neurol. 2011 Oct;70(4):634-45. doi: 10.1002/ana.22511.
Impact factor: 10.746
Publication type: Paper in international publication
Authors: Bustamante, Marta F, Fissolo, Nicolas, Rio, Jordi, Espejo, Carmen, Costa, Carme, Mansilla, Maria Jose, Lizasoain, Ignacio, Angeles Moro, Maria, Carmen Edo, Mari, Comabella, Manuel et al.
DOI: 10.1002/ana.22511

Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis.

PMID: 21992960
Journal: CLINICAL IMMUNOLOGY
Year: 2011
Reference: Clin Immunol. 2011 Dec;141(3):348-56. Epub 2011 Sep 21.
Impact factor: 3.932
Publication type: Paper in international publication
Authors: , , , , , , et al.
DOI: 10.1016/j.clim.2011.09.006

Search for Specific Biomarkers of IFNbeta Bioactivity in Patients with Multiple Sclerosis.

PMID: 21886806
Journal: PLoS One
Year: 2011
Reference: PLoS One. 2011;6(8):e23634. Epub 2011 Aug 23.
Impact factor: 4.411
Publication type: Paper in international publication
Authors: Malhotra, Sunny, Bustamante, Marta F, Perez-Miralles, Francisco, Rio, Jordi, Ruiz de Villa, Mari Carmen, Vegas, Esteban, Nonell, Lara, Deisenhammer, Florian, Fissolo, Nicolas, Nurtdinov, Ramil N et al.
DOI: 10.1371/journal.pone.0023634

Brainstem lesions in clinically isolated syndromes.

PMID: 21098409
Journal: NEUROLOGY
Year: 2010
Reference: Neurology. 2010 Nov 23;75(21):1933-8.
Impact factor: 8.172
Publication type: Paper in international publication
Authors: Tintore, M, Rovira, A, Arrambide, G, Mitjana, R, Rio, J, Auger, C, Nos, C, Edo, M C, Castillo, J, Horga, A et al.
DOI: 10.1212/WNL.0b013e3181feb26f

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

PMID: 20236661
Journal: JOURNAL OF THE NEUROLOGICAL SCIENCES
Year: 2010
Reference: J Neurol Sci. 2010 May 15;292(1-2):28-35. Epub 2010 Mar 16.
Impact factor: 2.324
Publication type: Paper in international publication
Authors: Strasser-Fuchs, S, Radue, Ernst-Wilhelm, Stuart, William H, Calabresi, Peter A, Confavreux, Christian, Galetta, Steven L, Rudick, Richard A, Lublin, Fred D, Weinstock-Guttman, Bianca, Wynn, Daniel R et al.
DOI: 10.1016/j.jns.2010.02.012

[Demyelinating lesions as incidental findings in magnetic resonance imaging: a study of 11 cases with clinico-radiological follow-up and a review of the literature]

PMID: 20645263
Journal: REVISTA DE NEUROLOGIA
Year: 2010
Reference: Rev Neurol. 2010 Aug;51(3):129-34.
Impact factor: 1.234
Publication type: Paper in national publication
Authors: Sierra-Marcos, Alba, Mitjana, Raquel, Castillo, Joaquin, Edo, Mari Carmen, Horga-Hernandez, Alejandro, Tintore, Mar, Rio-Izquierdo, Jordi, Auger-Acosta, Cristina, Rovira, Alex, Montalban, Xavier et al.
DOI:

Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS.

PMID: 19946780
Journal: JOURNAL OF NEUROLOGY
Year: 2010
Reference: J Neurol. 2010 May;257(5):742-6. Epub 2009 Nov 28.
Impact factor: 2.903
Publication type: Paper in international publication
Authors: Sastre-Garriga, Jaume, Tintore, M, Nos, C, Tur, C, Rio, J, Tellez, N, Castillo, J, Horga, A, Perkal, H, Comabella, M et al.
DOI: 10.1007/s00415-009-5403-0

Plasma levels of 15d-PGJ are not altered in multiple sclerosis.

PMID: 19538219
Journal: EUROPEAN JOURNAL OF NEUROLOGY
Year: 2009
Reference: Eur J Neurol. 2009 Nov;16(11):1197-201.
Impact factor: 2.732
Publication type: Paper in international publication
Authors: Comabella, M, Pradillo, J M, Fernandez, M, Rio, J, Lizasoain, I, Julia, E, Moro, M A, Sastre-Garriga, J, Montalban, X et al.
DOI: 10.1111/j.1468-1331.2009.02696.x

HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis.

PMID: 19349081
Journal: JOURNAL OF NEUROIMMUNOLOGY
Year: 2009
Reference: J Neuroimmunol. 2009 May 29;210(1-2):116-9.
Impact factor: 3.159
Publication type: Paper in international publication
Authors: Comabella, M, Fernandez-Arquero, M, Rio, J, Guinea, A, Fernandez, M, Cenit, M C, de la Concha, E G, Montalban, X et al.
DOI: 10.1016/j.jneuroim.2009.01.012

Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.

PMID: 18945642
Journal: CLINICAL IMMUNOLOGY
Year: 2009
Reference: Clin Immunol. 2009 Feb;130(2):145-50.
Impact factor: 3.606
Publication type: Paper in international publication
Authors: Montalban, Xavier, Oksenberg, Jorge R, Julia, Eva, Comabella, Manuel, Rio, Jordi, Espejo, Carmen, Ruiz de Villa, Mamen, Al-Zayat, Hammad, Nos, Carlos, Deisenhammer, Florian et al.
DOI: 10.1016/j.clim.2008.09.010

Plasma chitotriosidase activity in multiple sclerosis.

PMID: 19176289
Journal: CLINICAL IMMUNOLOGY
Year: 2009
Reference: Clin Immunol. 2009 May;131(2):216-22.
Impact factor: 3.606
Publication type: Paper in international publication
Authors: Vilches, A, Vilarrasa, N, Espejo, C, Montalban, X, Martin-Gallan, P, Rio, J, Dominguez, C, Comabella, M et al.
DOI: 10.1016/j.clim.2008.12.004

[Epileptic status due to non-ketotic hyperglycemia].

PMID: 15766515
Journal: MEDICINA CLINICA
Year: 2005
Reference: Med Clin (Barc). 2005 Mar 19;124(10):398-9. doi: 10.1157/13072580.
Impact factor: 1.005
Publication type: Letter or abstract
Authors: Rovira, Alex, Rio, Jordi, Purroy, Francesc, Toledo, Manuel et al.
DOI: 10.1157/13072580

Thesis

The gut microbiota as a therapeutic target in multiple sclerosis

PhD student: Laura Calvo Barreiro
Director/s: Carmen Espejo Ruiz, Herena Eixarch Ahufinger, Xavier Montalban Gairín
University: Universitat Autònoma de Barcelona
Year: 2020

Búsqueda de variantes genéticas causales y estudio de sus implicaciones funcionales en pacientes con esclerosis múltiple

PhD student: Elia Gil Varea
Director/s: Manuel Comabella Lopez, Sunny Malhotra Sareen, Xavier Montalban Gairín
University: Universitat Autònoma de Barcelona
Year: 2018

Estudio de pseudoatrofia cerebral en los pacientes con esclerosis múltiple

PhD student: Angela Vidal Jordana
Director/s: Xavier Montalban Gairín, Jaume Sastre Garriga
University: Universitat Autònoma de Barcelona
Year: 2016

Indicadores precoces de respuesta al tratamiento con interferón en pacientes con esclerosis múltiple

PhD student: Joaquin Castillo Justribo
Director/s: Xavier Montalban Gairín, Jordi Rio Izquierdo
University: Universitat Autònoma de Barcelona
Year: 2016

Brain Volume and Brain Metabolite Changes in the First Stages of Primary Progressive Multiple Sclerosis - A short-term longitudinal study

PhD student: Jaume Sastre Garriga
Director/s: Xavier Montalban Gairín
University: Universitat Autònoma de Barcelona
Year: 2015

Estudio clínico y de resonancia magnética del rendimiento cognitivo en síndromes neurológicos aislados sugestivos de esclerosis múltiple

PhD student: M Jesus Arevalo Navines
Director/s: Xavier Montalban Gairín
University: Universitat Autònoma de Barcelona
Year: 2014

Búsqueda de Biomarcadores Asociados con la Respuesta al Tratamiento con Interferón-beta en Pacientes con Esclerosis Múltiple Remitente-Recurrente.

PhD student: Manuel Comabella Lopez
Director/s: Xavier Montalban Gairín
University: Universitat Autònoma de Barcelona
Year: 2013

Estudio clínico y de resonancia magnética orientado al conocimiento del sustrato patológico de la discapacidad en la esclerosis múltiple primariamente progresiva

PhD student: Carmen Tur Gomez
Director/s: Vicenç Fonollosa Pla, Xavier Montalban Gairín
University: Universitat Autònoma de Barcelona
Year: 2012

Funció de les metalotioneínes en la patogenia de l’encefalomielitis autoimmune experimental i de l’esclerosi múltiple. Implicacions terapèutiques

PhD student: Carmen Espejo Ruiz
Director/s:
University: Universitat Autònoma de Barcelona
Year: 2005

Blog

News

The research led by Vall d'Hebron is a breakthrough in the search for specific and effective treatments for the disease.

The study conducted at Vall d'Hebron shows that having a high level of neurofilament light chains translates, over the years, to a higher level of disability.

The research aims to identify which patients with isolated radiological syndrome are more likely to develop the disease.

Job offers

CLINICAL RESEARCH COORDINATOR-Neuroimmunology research group - Multiple Sclerosis (MS)
Start date:
13/06/2022
End date:
27/06/2022
Document: Download
CLINICAL TRIALS TREATING NEUROLOGIST-Neuroimmunology research group - Multiple Sclerosis (MS) (8h)
Start date:
13/06/2022
End date:
27/06/2022
Document: Download
CLINICAL TRIALS TREATING NEUROLOGIST-Neuroimmunology research group - Multiple Sclerosis (MS) (32h)
Start date:
13/06/2022
End date:
27/06/2022
Document: Download